Tyr Pharma, Inc. (NASDAQ:ATYR), a clinical-stage biotechnology company valued at $286.24 million, is garnering attention from investors and analysts alike as it advances its lead candidate, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback